Drug Trial Radar · NCT00805467
Open-Label, Multicenter Extension Study for Patients Completing Treatment Phase of a Rigel-Sponsored R935788 Studies
Last checked: Nov 20, 2026Latest source record: Jun 25, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
624
Actual
Start
Aug 2008
Primary completion
Aug 2013
Study completion Aug 2013
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Dec 9, 2008
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this new research study is to gain additional information about how safe and effective R935788 is over a longer period of time.
Conditions
- Rheumatoid Arthritis
Interventions
Fostamatinib Disodium (R935788)Drug
50 mg PO BID; 100 mg PO BID; 100 mg PO QD; 150 mg tablet PO QD
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Patients Who Had at Least 1 Treatment Emergent Adverse Event in Any CategoryTime frame: Entry in extension to end of study, up to a maximum of 5 years. (Variable by subject - median duration of 3 years)
Locations
76 sites in 11 countries. Site status is shown where the registry gives one.
Research Site
La Jolla, California
Research Site
Palm Desert, California
Research Site
Palo Alto, California
Research Site
San Diego, California
Research Site
Santa Maria, California
Research Site
Hamden, Connecticut
Research Site
Washington D.C., District of Columbia
Research Site
Aventura, Florida
Research Site
Boca Raton, Florida
Research Site
Gainesville, Florida
Research Site
Ocala, Florida
Research Site
Orange Park, Florida
Research Site
Orlando, Florida
Research Site
South Miami, Florida
Research Site
Venice, Florida
Research Site
Boise, Idaho
Research Site
Coeur d'Alene, Idaho
Research Site
South Bend, Indiana
Research Site
Elizabethtown, Kentucky
Research Site
Cumberland, Maryland
Research Site
Hagerstown, Maryland
Research Site
Lansing, Michigan
Research Site
Omaha, Nebraska
Research Site
Roslyn, New York
Research Site
Smithtown, New York
Research Site
Raleigh, North Carolina
Research Site
Mayfiled Village, Ohio
Research Site
Erie, Pennsylvania
Research Site
Willow Grove, Pennsylvania
Research Site
Wyomissing, Pennsylvania
Research Site
Jackson, Tennessee
Research Site
Austin, Texas
Research Site
San Antonio, Texas
Research Site
Oklahoma City, Washington
Research Site
Spokane, Washington
Research Site
Antwerp, Belgium
Research Site
Ghent, Belgium
Research Site
Liège, Belgium
Research Site
Plovdiv, Bulgaria
Research Site
Rousse, Bulgaria
Showing 40 of 76 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.